Genpharmasec Ltd
Incorporated in 1992, Generic Pharmasec
Ltd deals in pharmaceutical activities /services and trades in equity shares[1]
- Market Cap ₹ 134 Cr.
- Current Price ₹ 2.42
- High / Low ₹ 7.31 / 1.69
- Stock P/E
- Book Value ₹ 1.16
- Dividend Yield 0.00 %
- ROCE 1.52 %
- ROE -0.33 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -30.0%
- Promoter holding is low: 30.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | |
---|---|---|
25.52 | 30.41 | |
25.26 | 30.37 | |
Operating Profit | 0.26 | 0.04 |
OPM % | 1.02% | 0.13% |
0.10 | 0.66 | |
Interest | 0.06 | 0.41 |
Depreciation | 0.02 | 0.04 |
Profit before tax | 0.28 | 0.25 |
Tax % | -300.00% | 168.00% |
1.12 | -0.17 | |
EPS in Rs | 0.02 | -0.00 |
Dividend Payout % | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -112% |
Stock Price CAGR | |
---|---|
10 Years: | 10% |
5 Years: | -21% |
3 Years: | -26% |
1 Year: | 15% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | |
---|---|---|
Equity Capital | 27.69 | 55.37 |
Reserves | -12.36 | 9.02 |
3.08 | 3.89 | |
1.46 | 2.84 | |
Total Liabilities | 19.87 | 71.12 |
0.10 | 0.84 | |
CWIP | 0.00 | 0.00 |
Investments | 0.95 | 19.32 |
18.82 | 50.96 | |
Total Assets | 19.87 | 71.12 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | |
---|---|---|
-3.06 | -2.95 | |
0.36 | -28.06 | |
3.08 | 47.85 | |
Net Cash Flow | 0.39 | 16.84 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | |
---|---|---|
Debtor Days | 81.67 | 109.22 |
Inventory Days | 151.06 | 133.17 |
Days Payable | 21.38 | 35.85 |
Cash Conversion Cycle | 211.34 | 206.54 |
Working Capital Days | 207.67 | 213.17 |
ROCE % | 1.52% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Jul - Newspaper Publication of Notice of AGM under Regulation 30 and 47 of SEBI (LODR) Regulation, 2015.
- Reg. 34 (1) Annual Report. 1 Jul
- Notice Of 32Nd Annual General Meeting To Be Held On July 23, 2024. 1 Jul
- Intimation Of Book Closure For Annual General Meeting. 27 Jun
- Board Meeting Outcome for Outcome Of The Meeting Of Board Held On Thursday, 27Th June, 2024 At 02:30 P.M. 27 Jun
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
GPL started as a manufacturer and trader of organic and inorganic chemicals, dyes and pigments and then shifted its business activities to buying, selling and distribution of pharmaceutical, medicinal and medicated preparations and also decided to deal in securities market. Currently, company is dealing in medical and diagnostics devices